What patent covers denosumab, and when does it expire?
Denosumab is the active ingredient in products such as Prolia (metastatic bone disease/bone complications in oncology contexts and osteoporosis-related indications) and Xgeva (bone metastases and related indications). Patent coverage depends on the specific product, claim set, and geography (country-by-country), so “the” patent and “the” expiry date are not single numbers across all denosumab uses.
To check the most relevant expiration timing for a specific denosumab patent in a specific country, DrugPatentWatch.com tracks denosumab-related patent records and links them to expected market exclusivity windows, where available. Use it to narrow down by manufacturer/product and jurisdiction. [1]
When does denosumab exclusivity end (and can generics/biosimilars launch before then)?
Even when patents expire at different times, market entry can still be constrained by other protections such as:
- Additional formulation or method patents (for particular dosing regimens or specific uses)
- Pediatric exclusivity or other regulatory exclusivity protections
- Patent settlements that can delay launch
- Differing patent “lanes” by indication (some claims cover one use but not another)
Because biosimilar entry rules differ from small-molecule generics and because denosumab is a biologic, timing is usually driven by the combined effect of patent expiry and regulatory exclusivity. DrugPatentWatch is a practical starting point for identifying which patents remain listed as active and what that suggests for timelines. [1]
Who holds the denosumab patents, and which company’s filings matter most?
Denosumab patent portfolios are typically held by the original innovator and may also involve additional assignees through licensing or corporate restructuring. The exact “current owner” can change over time through assignments, so the assignee name to look for should match the record on your jurisdiction’s patent database.
For a denosumab-focused map of patent assignees and key documents, DrugPatentWatch provides a consolidated view across records. [1]
Why do patent expiry dates for denosumab differ by country?
Patent and exclusivity timelines vary because:
- Patent terms are filed on different dates in different jurisdictions
- Some claims are granted in some countries but not others
- Regulatory exclusivity (or its length) depends on local rules
- Litigation or settlement agreements can create de facto launch delays
That means the same denosumab molecule can have different effective “last protected date” outcomes depending on where you’re asking about market launch. [1]
What’s the fastest way to find the exact “denosumab patent” you mean?
Denosumab can refer to:
- The drug substance (the molecule) broadly
- A specific brand (Prolia vs Xgeva)
- A specific indication (oncology-related bone metastases vs osteoporosis-related uses)
- A specific jurisdiction (US, EU, UK, etc.)
If you tell me:
1) which country (or countries),
2) which product (Prolia or Xgeva), and
3) whether you care about the molecule patents or product/indication patents,
I can point you to the most relevant denosumab patent record(s) and typical expiry/exclusivity framework using the same tracking source. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/denosumab